Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Oleclumab in NSCLC and RCC (DOMINATION)
NCT04262375Phase 2Withdrawn
- Sponsor
- University Health Network
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of oleclumab in non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), sponsored by University Health Network. Primary endpoint: Association between cfMeDIP and Response/Toxicity at 3 years. Planned start Jan 2021; status: withdrawn.
02
Drugs
oleclumab
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04262375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262375.